Chlamydia in Testicular Tissue Linked to Male Infertility
|
By LabMedica International staff writers Posted on 26 Oct 2019 |

Image: The histological detection of chlamydia in human testicular biopsies (Photo courtesy of Queensland University of Technology).
Infectious diseases, such as mumps virus infection of the human testis, are known to play a role in spermatogenic dysfunction and have been associated with abnormal sperm parameters. Bacteria including Escherichia coli, mycoplasmas and Chlamydia trachomatis in human semen are also associated with abnormal sperm parameters.
The potential impact of undiagnosed sexually transmitted chlamydia infection on men's fertility has been highlighted in a study, which for the first time found chlamydia in the testicular tissue biopsies of infertile men whose infertility had no identified cause. Challenges in attributing male infertility to chlamydia infection include a wide diversity in diagnostic approaches.
Biomedical scientists at the Queensland University of Technology (Herston, Australia) collected 100 diagnostic (fixed) and 18 therapeutic (fresh) human testicular biopsies during sperm recovery procedures from moderately to severely infertile men in a cross-sectional approach to sampling. Two chlamydial markers were detected: the general marker major outer membrane protein (MOMP) and the active replication marker TC0500. Sections of 4 μm were dewaxed and rehydrated using a Leica ST5010-CV5030 Integrated Workstation.
The slides were processed and staining was validated using primary antibody only, secondary antibody only and DAB only controls. Stained slides were scanned using Leica Biosystems’ Aperio AT Turbo. QIAamp DNA FFPE Tissue Kit was used to extract DNA from fixed biopsies. C. trachomatis 16S rRNA DNA was detected using real-time polymerase chain reaction. Serum samples matched to fresh biopsies were assayed for C. trachomatis-specific antibodies.
The scientists reported that Chlamydia was found in 43/95 men (45.3 %) of fixed testicular biopsies, and all the men in this group had no defined cause of infertility. Chlamydia was also found in 3/18 men (16.7 %) of fresh testicular biopsies, obtained during patient sperm recovery procedures. These three men, and another 10 in the group, had no identified cause for their infertility. In 12 of the 18 men providing the fresh biopsies (66.7%) Chlamydia trachomatis-specific antibodies were found in serum, indicating the men had been exposed to the bacteria, but all were asymptomatic and said they had not been diagnosed with any sexually transmitted infection.
Kenneth W. Beagley, PhD, a Professor of Immunology and a senior author of the study said, “Chlamydia infection has been associated with women's infertility but much less is known about its impact on male infertility, particularly if men do not experience symptoms, which is estimated to be in about 50% of cases. When people have no symptoms they can unknowingly pass on the infection to sexual partners. This is the first reported evidence of Chlamydia infection in human testicular tissue, and while it can't be said that Chlamydia was the cause of the infertility of the men, it is a significant finding. It reveals a high rate of previously unrecognized Chlamydia infection and the potential role of infection in the failure of sperm to develop in the testes.” The study was published on October 4, 2019, in the journal Human Reproduction.
Related Links:
Queensland University of Technology
The potential impact of undiagnosed sexually transmitted chlamydia infection on men's fertility has been highlighted in a study, which for the first time found chlamydia in the testicular tissue biopsies of infertile men whose infertility had no identified cause. Challenges in attributing male infertility to chlamydia infection include a wide diversity in diagnostic approaches.
Biomedical scientists at the Queensland University of Technology (Herston, Australia) collected 100 diagnostic (fixed) and 18 therapeutic (fresh) human testicular biopsies during sperm recovery procedures from moderately to severely infertile men in a cross-sectional approach to sampling. Two chlamydial markers were detected: the general marker major outer membrane protein (MOMP) and the active replication marker TC0500. Sections of 4 μm were dewaxed and rehydrated using a Leica ST5010-CV5030 Integrated Workstation.
The slides were processed and staining was validated using primary antibody only, secondary antibody only and DAB only controls. Stained slides were scanned using Leica Biosystems’ Aperio AT Turbo. QIAamp DNA FFPE Tissue Kit was used to extract DNA from fixed biopsies. C. trachomatis 16S rRNA DNA was detected using real-time polymerase chain reaction. Serum samples matched to fresh biopsies were assayed for C. trachomatis-specific antibodies.
The scientists reported that Chlamydia was found in 43/95 men (45.3 %) of fixed testicular biopsies, and all the men in this group had no defined cause of infertility. Chlamydia was also found in 3/18 men (16.7 %) of fresh testicular biopsies, obtained during patient sperm recovery procedures. These three men, and another 10 in the group, had no identified cause for their infertility. In 12 of the 18 men providing the fresh biopsies (66.7%) Chlamydia trachomatis-specific antibodies were found in serum, indicating the men had been exposed to the bacteria, but all were asymptomatic and said they had not been diagnosed with any sexually transmitted infection.
Kenneth W. Beagley, PhD, a Professor of Immunology and a senior author of the study said, “Chlamydia infection has been associated with women's infertility but much less is known about its impact on male infertility, particularly if men do not experience symptoms, which is estimated to be in about 50% of cases. When people have no symptoms they can unknowingly pass on the infection to sexual partners. This is the first reported evidence of Chlamydia infection in human testicular tissue, and while it can't be said that Chlamydia was the cause of the infertility of the men, it is a significant finding. It reveals a high rate of previously unrecognized Chlamydia infection and the potential role of infection in the failure of sperm to develop in the testes.” The study was published on October 4, 2019, in the journal Human Reproduction.
Related Links:
Queensland University of Technology
Latest Microbiology News
- Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
- Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
- Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
- FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
- One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
- Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus
- Genetic Studies Uncover Mechanisms Driving Drug Resistance in Superbugs
- Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
- Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
- Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
Channels
Clinical Chemistry
view channel
Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome
Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more
Study Questions Broad Fasting Requirements Before Routine Blood Tests
Routine blood testing is central to diagnosis, monitoring, and disease risk assessment. Many patients are still asked to fast for 8–12 hours before phlebotomy, even though the requirement was originally... Read more
Elevated Lipoprotein(a) Linked to Long-Term Progression of Carotid Atherosclerosis
Lipoprotein(a), or Lp(a), is a genetically determined blood lipid and an important risk factor for cardiovascular disease. Its relationship to long-term carotid atherosclerosis has remained unclear, particularly... Read moreMolecular Diagnostics
view channel
Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants
Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more
New NGS Suite Expands Clonality and MRD Research in Lymphoid Malignancies
Lymphoid malignancies require molecular tools that can distinguish clonal immune receptor rearrangements and track disease-related sequences over time. As immune receptor measurable residual disease analysis... Read more
Tumor-Informed ctDNA Test Shows Utility Across Gastrointestinal and Gynecologic Cancers
Natera announced new data on Signatera, its tumor-informed circulating tumor DNA test, that were presented in four oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Single-Tier Lyme Disease Test Shows High Sensitivity in Early Infection
Lyme disease can be difficult to diagnose during the earliest stages of infection, when conventional serologic testing may have limited sensitivity. Patients may present during a diagnostic gray zone in... Read more
New Web-Based Platform Helps Autoimmune Laboratories Manage Testing Complexity
Autoimmune disease testing often requires laboratories to coordinate results across multiple instruments, manual microscopy, and patient histories. As testing volumes and workflow complexity increase,... Read morePathology
view channel
Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Glioma brain tumors are highly infiltrative and can extend into nearby healthy brain tissue, making tumor margins difficult to define during surgery. Residual tumor cells may contribute to recurrence and... Read more
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read moreTechnology
view channelLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read moreIndustry
view channel
Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China
Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Collaboration Advances Automated Benchtop Platform for Routine Blood Testing
Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Expanded Partnership Supports AI Biomarker Validation and Clinical Trial Deployment
CellCarta (Montreal, Canada) and Imagene AI (Miami, FL, USA) have expanded their collaboration to provide biopharma companies with a coordinated pathway for biomarker strategy, assay development, validation,... Read more







